Acutus Medical, Inc.
Acutus Medical, Inc. AFIB Peers
See (AFIB) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AFIB | $0.00 | -33.33% | 53.8K | -0.01 | -$0.15 | N/A |
| ABT | $133.67 | -2.71% | 232.6B | 17.38 | $7.69 | +1.71% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $104.58 | +0.28% | 154.7B | 76.34 | $1.37 | N/A |
| SYK | $390.40 | -0.47% | 149.2B | 52.83 | $7.39 | +0.84% |
| MDT | $86.18 | +0.24% | 110.5B | 23.89 | $3.61 | +3.26% |
| EW | $77.15 | +0.23% | 45.3B | 31.88 | $2.42 | N/A |
| DXCM | $85.04 | +0.43% | 33.4B | 63.95 | $1.33 | N/A |
| STE | $238.53 | -0.77% | 23.5B | 38.65 | $6.17 | +0.96% |
| PHG | $24.08 | +0.67% | 22.3B | 80.27 | $0.30 | +3.68% |
Stock Comparison
AFIB vs ABT Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, ABT has a market cap of 232.6B. Regarding current trading prices, AFIB is priced at $0.00, while ABT trades at $133.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas ABT's P/E ratio is 17.38. In terms of profitability, AFIB's ROE is +1.24%, compared to ABT's ROE of +0.31%. Regarding short-term risk, AFIB is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs BSX-PA Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, AFIB is priced at $0.00, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, AFIB's ROE is +1.24%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, AFIB is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs BSX Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, BSX has a market cap of 154.7B. Regarding current trading prices, AFIB is priced at $0.00, while BSX trades at $104.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas BSX's P/E ratio is 76.34. In terms of profitability, AFIB's ROE is +1.24%, compared to BSX's ROE of +0.10%. Regarding short-term risk, AFIB is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs SYK Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, SYK has a market cap of 149.2B. Regarding current trading prices, AFIB is priced at $0.00, while SYK trades at $390.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas SYK's P/E ratio is 52.83. In terms of profitability, AFIB's ROE is +1.24%, compared to SYK's ROE of +0.11%. Regarding short-term risk, AFIB is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs MDT Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, MDT has a market cap of 110.5B. Regarding current trading prices, AFIB is priced at $0.00, while MDT trades at $86.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas MDT's P/E ratio is 23.89. In terms of profitability, AFIB's ROE is +1.24%, compared to MDT's ROE of +0.10%. Regarding short-term risk, AFIB is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs EW Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, EW has a market cap of 45.3B. Regarding current trading prices, AFIB is priced at $0.00, while EW trades at $77.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas EW's P/E ratio is 31.88. In terms of profitability, AFIB's ROE is +1.24%, compared to EW's ROE of +0.49%. Regarding short-term risk, AFIB is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs DXCM Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, DXCM has a market cap of 33.4B. Regarding current trading prices, AFIB is priced at $0.00, while DXCM trades at $85.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas DXCM's P/E ratio is 63.95. In terms of profitability, AFIB's ROE is +1.24%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, AFIB is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs STE Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, STE has a market cap of 23.5B. Regarding current trading prices, AFIB is priced at $0.00, while STE trades at $238.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas STE's P/E ratio is 38.65. In terms of profitability, AFIB's ROE is +1.24%, compared to STE's ROE of +0.09%. Regarding short-term risk, AFIB is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs PHG Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, PHG has a market cap of 22.3B. Regarding current trading prices, AFIB is priced at $0.00, while PHG trades at $24.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas PHG's P/E ratio is 80.27. In terms of profitability, AFIB's ROE is +1.24%, compared to PHG's ROE of +0.03%. Regarding short-term risk, AFIB is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs PODD Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, PODD has a market cap of 21.8B. Regarding current trading prices, AFIB is priced at $0.00, while PODD trades at $309.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas PODD's P/E ratio is 55.83. In terms of profitability, AFIB's ROE is +1.24%, compared to PODD's ROE of +0.35%. Regarding short-term risk, AFIB is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs ZBH Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, ZBH has a market cap of 18.2B. Regarding current trading prices, AFIB is priced at $0.00, while ZBH trades at $91.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas ZBH's P/E ratio is 20.39. In terms of profitability, AFIB's ROE is +1.24%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, AFIB is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs ABMD Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, AFIB is priced at $0.00, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas ABMD's P/E ratio is 65.36. In terms of profitability, AFIB's ROE is +1.24%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, AFIB is less volatile compared to ABMD. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs ALGN Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, ALGN has a market cap of 13.6B. Regarding current trading prices, AFIB is priced at $0.00, while ALGN trades at $187.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas ALGN's P/E ratio is 34.07. In terms of profitability, AFIB's ROE is +1.24%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, AFIB is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs SNN Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, SNN has a market cap of 13.2B. Regarding current trading prices, AFIB is priced at $0.00, while SNN trades at $30.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas SNN's P/E ratio is 32.12. In terms of profitability, AFIB's ROE is +1.24%, compared to SNN's ROE of +0.08%. Regarding short-term risk, AFIB is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs SWAV Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, AFIB is priced at $0.00, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas SWAV's P/E ratio is 78.76. In terms of profitability, AFIB's ROE is +1.24%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, AFIB is less volatile compared to SWAV. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs PEN Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, PEN has a market cap of 9.8B. Regarding current trading prices, AFIB is priced at $0.00, while PEN trades at $253.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas PEN's P/E ratio is 234.66. In terms of profitability, AFIB's ROE is +1.24%, compared to PEN's ROE of +0.04%. Regarding short-term risk, AFIB is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs GMED Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, GMED has a market cap of 8B. Regarding current trading prices, AFIB is priced at $0.00, while GMED trades at $58.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas GMED's P/E ratio is 43.87. In terms of profitability, AFIB's ROE is +1.24%, compared to GMED's ROE of +0.05%. Regarding short-term risk, AFIB is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs BIO Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, BIO has a market cap of 6.6B. Regarding current trading prices, AFIB is priced at $0.00, while BIO trades at $243.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas BIO's P/E ratio is -3.18. In terms of profitability, AFIB's ROE is +1.24%, compared to BIO's ROE of -0.32%. Regarding short-term risk, AFIB is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs BRKR Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, BRKR has a market cap of 6.4B. Regarding current trading prices, AFIB is priced at $0.00, while BRKR trades at $42.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas BRKR's P/E ratio is 81.12. In terms of profitability, AFIB's ROE is +1.24%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, AFIB is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs BIO-B Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, BIO-B has a market cap of 6.3B. Regarding current trading prices, AFIB is priced at $0.00, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas BIO-B's P/E ratio is -3.27. In terms of profitability, AFIB's ROE is +1.24%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, AFIB and BIO-B have similar daily volatility (0.00).
AFIB vs GKOS Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, GKOS has a market cap of 5.8B. Regarding current trading prices, AFIB is priced at $0.00, while GKOS trades at $101.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas GKOS's P/E ratio is -44.52. In terms of profitability, AFIB's ROE is +1.24%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, AFIB is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs IRTC Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, IRTC has a market cap of 4.9B. Regarding current trading prices, AFIB is priced at $0.00, while IRTC trades at $152.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas IRTC's P/E ratio is -48.94. In terms of profitability, AFIB's ROE is +1.24%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, AFIB is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs NARI Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, AFIB is priced at $0.00, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas NARI's P/E ratio is -59.24. In terms of profitability, AFIB's ROE is +1.24%, compared to NARI's ROE of -0.18%. Regarding short-term risk, AFIB is less volatile compared to NARI. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs TMDX Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, TMDX has a market cap of 4.4B. Regarding current trading prices, AFIB is priced at $0.00, while TMDX trades at $130.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas TMDX's P/E ratio is 91.59. In terms of profitability, AFIB's ROE is +1.24%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, AFIB is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs ITGR Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, AFIB is priced at $0.00, while ITGR trades at $121.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas ITGR's P/E ratio is 56.67. In terms of profitability, AFIB's ROE is +1.24%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, AFIB is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs INSP Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, INSP has a market cap of 3.8B. Regarding current trading prices, AFIB is priced at $0.00, while INSP trades at $129.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas INSP's P/E ratio is 59.19. In terms of profitability, AFIB's ROE is +1.24%, compared to INSP's ROE of +0.10%. Regarding short-term risk, AFIB is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs AXNX Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, AFIB is priced at $0.00, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas AXNX's P/E ratio is -709.80. In terms of profitability, AFIB's ROE is +1.24%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, AFIB and AXNX have similar daily volatility (0.00).
AFIB vs PRCT Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, PRCT has a market cap of 3.2B. Regarding current trading prices, AFIB is priced at $0.00, while PRCT trades at $58.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas PRCT's P/E ratio is -34.69. In terms of profitability, AFIB's ROE is +1.24%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, AFIB is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs LIVN Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, LIVN has a market cap of 2.5B. Regarding current trading prices, AFIB is priced at $0.00, while LIVN trades at $45.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas LIVN's P/E ratio is -11.25. In terms of profitability, AFIB's ROE is +1.24%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, AFIB is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs NUVA Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, AFIB is priced at $0.00, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas NUVA's P/E ratio is 75.00. In terms of profitability, AFIB's ROE is +1.24%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, AFIB is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs UFPT Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, UFPT has a market cap of 1.9B. Regarding current trading prices, AFIB is priced at $0.00, while UFPT trades at $247.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas UFPT's P/E ratio is 30.32. In terms of profitability, AFIB's ROE is +1.24%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, AFIB is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs CNMD Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, CNMD has a market cap of 1.6B. Regarding current trading prices, AFIB is priced at $0.00, while CNMD trades at $52.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas CNMD's P/E ratio is 13.73. In terms of profitability, AFIB's ROE is +1.24%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, AFIB is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs ATEC Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, AFIB is priced at $0.00, while ATEC trades at $10.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas ATEC's P/E ratio is -9.56. In terms of profitability, AFIB's ROE is +1.24%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, AFIB is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs HSKA Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, AFIB is priced at $0.00, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas HSKA's P/E ratio is -62.49. In terms of profitability, AFIB's ROE is +1.24%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, AFIB and HSKA have similar daily volatility (0.00).
AFIB vs AORT Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, AFIB is priced at $0.00, while AORT trades at $30.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas AORT's P/E ratio is -60.06. In terms of profitability, AFIB's ROE is +1.24%, compared to AORT's ROE of -0.07%. Regarding short-term risk, AFIB is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs TNDM Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, AFIB is priced at $0.00, while TNDM trades at $19.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas TNDM's P/E ratio is -6.85. In terms of profitability, AFIB's ROE is +1.24%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, AFIB is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs AHCO Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, AFIB is priced at $0.00, while AHCO trades at $9.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas AHCO's P/E ratio is 16.24. In terms of profitability, AFIB's ROE is +1.24%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, AFIB is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs SSII Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, SSII has a market cap of 1.3B. Regarding current trading prices, AFIB is priced at $0.00, while SSII trades at $6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas SSII's P/E ratio is -81.75. In terms of profitability, AFIB's ROE is +1.24%, compared to SSII's ROE of -1.33%. Regarding short-term risk, AFIB is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs ESTA Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, ESTA has a market cap of 1.2B. Regarding current trading prices, AFIB is priced at $0.00, while ESTA trades at $40.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas ESTA's P/E ratio is -13.09. In terms of profitability, AFIB's ROE is +1.24%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, AFIB is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs SILK Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, AFIB is priced at $0.00, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas SILK's P/E ratio is -18.96. In terms of profitability, AFIB's ROE is +1.24%, compared to SILK's ROE of -0.29%. Regarding short-term risk, AFIB is less volatile compared to SILK. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs FNA Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, AFIB is priced at $0.00, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas FNA's P/E ratio is -19.83. In terms of profitability, AFIB's ROE is +1.24%, compared to FNA's ROE of -0.36%. Regarding short-term risk, AFIB is less volatile compared to FNA. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs INMD Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, INMD has a market cap of 978.7M. Regarding current trading prices, AFIB is priced at $0.00, while INMD trades at $14.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas INMD's P/E ratio is 6.31. In terms of profitability, AFIB's ROE is +1.24%, compared to INMD's ROE of +0.25%. Regarding short-term risk, AFIB is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs IART Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, IART has a market cap of 948.9M. Regarding current trading prices, AFIB is priced at $0.00, while IART trades at $12.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas IART's P/E ratio is -32.13. In terms of profitability, AFIB's ROE is +1.24%, compared to IART's ROE of -0.03%. Regarding short-term risk, AFIB is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs CSII Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, CSII has a market cap of 844M. Regarding current trading prices, AFIB is priced at $0.00, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas CSII's P/E ratio is -20.83. In terms of profitability, AFIB's ROE is +1.24%, compared to CSII's ROE of -0.14%. Regarding short-term risk, AFIB is less volatile compared to CSII. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs SIBN Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, SIBN has a market cap of 770.9M. Regarding current trading prices, AFIB is priced at $0.00, while SIBN trades at $18.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas SIBN's P/E ratio is -28.71. In terms of profitability, AFIB's ROE is +1.24%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, AFIB is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs IRMD Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, IRMD has a market cap of 770.7M. Regarding current trading prices, AFIB is priced at $0.00, while IRMD trades at $60.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas IRMD's P/E ratio is 39.11. In terms of profitability, AFIB's ROE is +1.24%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, AFIB is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs CRY Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, AFIB is priced at $0.00, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas CRY's P/E ratio is 425.71. In terms of profitability, AFIB's ROE is +1.24%, compared to CRY's ROE of -0.07%. Regarding short-term risk, AFIB is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs CBLL Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, CBLL has a market cap of 697.2M. Regarding current trading prices, AFIB is priced at $0.00, while CBLL trades at $19.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas CBLL's P/E ratio is -15.43. In terms of profitability, AFIB's ROE is +1.24%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, AFIB is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs APEN Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, AFIB is priced at $0.00, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas APEN's P/E ratio is -9.43. In terms of profitability, AFIB's ROE is +1.24%, compared to APEN's ROE of -0.85%. Regarding short-term risk, AFIB is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs BFLY-WT Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, BFLY-WT has a market cap of 578M. Regarding current trading prices, AFIB is priced at $0.00, while BFLY-WT trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, AFIB's ROE is +1.24%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, AFIB is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs AVNS Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, AVNS has a market cap of 562.3M. Regarding current trading prices, AFIB is priced at $0.00, while AVNS trades at $12.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas AVNS's P/E ratio is -1.47. In terms of profitability, AFIB's ROE is +1.24%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, AFIB is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs KIDS Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, KIDS has a market cap of 539.2M. Regarding current trading prices, AFIB is priced at $0.00, while KIDS trades at $21.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas KIDS's P/E ratio is -12.37. In terms of profitability, AFIB's ROE is +1.24%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, AFIB is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs RXST Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, RXST has a market cap of 537.6M. Regarding current trading prices, AFIB is priced at $0.00, while RXST trades at $13.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas RXST's P/E ratio is -20.05. In terms of profitability, AFIB's ROE is +1.24%, compared to RXST's ROE of -0.10%. Regarding short-term risk, AFIB is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs BFLY Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, BFLY has a market cap of 499.5M. Regarding current trading prices, AFIB is priced at $0.00, while BFLY trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas BFLY's P/E ratio is -6.73. In terms of profitability, AFIB's ROE is +1.24%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, AFIB is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs AXGN Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, AXGN has a market cap of 476.4M. Regarding current trading prices, AFIB is priced at $0.00, while AXGN trades at $10.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas AXGN's P/E ratio is -65.37. In terms of profitability, AFIB's ROE is +1.24%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, AFIB is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs CTKB Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, CTKB has a market cap of 449.6M. Regarding current trading prices, AFIB is priced at $0.00, while CTKB trades at $3.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas CTKB's P/E ratio is -39.44. In terms of profitability, AFIB's ROE is +1.24%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, AFIB is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs BVS Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, BVS has a market cap of 441.9M. Regarding current trading prices, AFIB is priced at $0.00, while BVS trades at $6.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas BVS's P/E ratio is -13.87. In terms of profitability, AFIB's ROE is +1.24%, compared to BVS's ROE of -0.21%. Regarding short-term risk, AFIB is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs SMLR Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, SMLR has a market cap of 432.6M. Regarding current trading prices, AFIB is priced at $0.00, while SMLR trades at $38.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas SMLR's P/E ratio is -16.23. In terms of profitability, AFIB's ROE is +1.24%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, AFIB is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs OFIX Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, OFIX has a market cap of 432.6M. Regarding current trading prices, AFIB is priced at $0.00, while OFIX trades at $11.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas OFIX's P/E ratio is -2.98. In terms of profitability, AFIB's ROE is +1.24%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, AFIB is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs SRDX Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, SRDX has a market cap of 416M. Regarding current trading prices, AFIB is priced at $0.00, while SRDX trades at $29.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas SRDX's P/E ratio is -20.78. In terms of profitability, AFIB's ROE is +1.24%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, AFIB is less volatile compared to SRDX. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs PACB Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, PACB has a market cap of 387.1M. Regarding current trading prices, AFIB is priced at $0.00, while PACB trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas PACB's P/E ratio is -0.47. In terms of profitability, AFIB's ROE is +1.24%, compared to PACB's ROE of -1.70%. Regarding short-term risk, AFIB is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs SENS Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, SENS has a market cap of 377.3M. Regarding current trading prices, AFIB is priced at $0.00, while SENS trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas SENS's P/E ratio is -4.55. In terms of profitability, AFIB's ROE is +1.24%, compared to SENS's ROE of -7.46%. Regarding short-term risk, AFIB is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs NPCE Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, NPCE has a market cap of 358.8M. Regarding current trading prices, AFIB is priced at $0.00, while NPCE trades at $10.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas NPCE's P/E ratio is -13.34. In terms of profitability, AFIB's ROE is +1.24%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, AFIB is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs OM Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, OM has a market cap of 356.7M. Regarding current trading prices, AFIB is priced at $0.00, while OM trades at $20.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas OM's P/E ratio is -0.70. In terms of profitability, AFIB's ROE is +1.24%, compared to OM's ROE of -1.45%. Regarding short-term risk, AFIB is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs VREX Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, VREX has a market cap of 354.4M. Regarding current trading prices, AFIB is priced at $0.00, while VREX trades at $8.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas VREX's P/E ratio is -8.29. In terms of profitability, AFIB's ROE is +1.24%, compared to VREX's ROE of -0.08%. Regarding short-term risk, AFIB is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs TMCI Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, TMCI has a market cap of 351.6M. Regarding current trading prices, AFIB is priced at $0.00, while TMCI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas TMCI's P/E ratio is -6.58. In terms of profitability, AFIB's ROE is +1.24%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, AFIB is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs NNOX Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, NNOX has a market cap of 343M. Regarding current trading prices, AFIB is priced at $0.00, while NNOX trades at $5.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas NNOX's P/E ratio is -5.91. In terms of profitability, AFIB's ROE is +1.24%, compared to NNOX's ROE of -0.31%. Regarding short-term risk, AFIB is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs CLPT Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, CLPT has a market cap of 339.7M. Regarding current trading prices, AFIB is priced at $0.00, while CLPT trades at $12.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas CLPT's P/E ratio is -15.82. In terms of profitability, AFIB's ROE is +1.24%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, AFIB is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs SNWV Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, SNWV has a market cap of 282.7M. Regarding current trading prices, AFIB is priced at $0.00, while SNWV trades at $33.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas SNWV's P/E ratio is -5.30. In terms of profitability, AFIB's ROE is +1.24%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, AFIB is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs VMD Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, VMD has a market cap of 273.1M. Regarding current trading prices, AFIB is priced at $0.00, while VMD trades at $6.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas VMD's P/E ratio is 23.03. In terms of profitability, AFIB's ROE is +1.24%, compared to VMD's ROE of +0.10%. Regarding short-term risk, AFIB is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs CATX Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, CATX has a market cap of 268M. Regarding current trading prices, AFIB is priced at $0.00, while CATX trades at $3.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas CATX's P/E ratio is -2.93. In terms of profitability, AFIB's ROE is +1.24%, compared to CATX's ROE of -0.27%. Regarding short-term risk, AFIB is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs CERS Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, CERS has a market cap of 260M. Regarding current trading prices, AFIB is priced at $0.00, while CERS trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas CERS's P/E ratio is -13.60. In terms of profitability, AFIB's ROE is +1.24%, compared to CERS's ROE of -0.35%. Regarding short-term risk, AFIB is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs QTRX Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, QTRX has a market cap of 255.3M. Regarding current trading prices, AFIB is priced at $0.00, while QTRX trades at $6.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas QTRX's P/E ratio is -5.30. In terms of profitability, AFIB's ROE is +1.24%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, AFIB is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs ZIMV Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, ZIMV has a market cap of 251.3M. Regarding current trading prices, AFIB is priced at $0.00, while ZIMV trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas ZIMV's P/E ratio is -10.00. In terms of profitability, AFIB's ROE is +1.24%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, AFIB is less volatile compared to ZIMV. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs PTHL Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, PTHL has a market cap of 249.2M. Regarding current trading prices, AFIB is priced at $0.00, while PTHL trades at $17.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas PTHL's P/E ratio is -349.80. In terms of profitability, AFIB's ROE is +1.24%, compared to PTHL's ROE of -0.30%. Regarding short-term risk, AFIB is less volatile compared to PTHL. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs BWAY Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, BWAY has a market cap of 245.8M. Regarding current trading prices, AFIB is priced at $0.00, while BWAY trades at $13.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas BWAY's P/E ratio is 59.14. In terms of profitability, AFIB's ROE is +1.24%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, AFIB is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs MXCT Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, MXCT has a market cap of 244.5M. Regarding current trading prices, AFIB is priced at $0.00, while MXCT trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas MXCT's P/E ratio is -5.75. In terms of profitability, AFIB's ROE is +1.24%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, AFIB is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs MASS Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, MASS has a market cap of 241.7M. Regarding current trading prices, AFIB is priced at $0.00, while MASS trades at $6.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas MASS's P/E ratio is -3.04. In terms of profitability, AFIB's ROE is +1.24%, compared to MASS's ROE of -0.13%. Regarding short-term risk, AFIB is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs TCMD Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, TCMD has a market cap of 238.1M. Regarding current trading prices, AFIB is priced at $0.00, while TCMD trades at $10.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas TCMD's P/E ratio is 15.52. In terms of profitability, AFIB's ROE is +1.24%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, AFIB is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs BSGM Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, BSGM has a market cap of 231.5M. Regarding current trading prices, AFIB is priced at $0.00, while BSGM trades at $8.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas BSGM's P/E ratio is -16.00. In terms of profitability, AFIB's ROE is +1.24%, compared to BSGM's ROE of -35.30%. Regarding short-term risk, AFIB is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs NVRO Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, AFIB is priced at $0.00, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas NVRO's P/E ratio is -1.91. In terms of profitability, AFIB's ROE is +1.24%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, AFIB is less volatile compared to NVRO. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs SGHT Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, SGHT has a market cap of 219.7M. Regarding current trading prices, AFIB is priced at $0.00, while SGHT trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas SGHT's P/E ratio is -4.34. In terms of profitability, AFIB's ROE is +1.24%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, AFIB is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs EYES Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, EYES has a market cap of 210M. Regarding current trading prices, AFIB is priced at $0.00, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas EYES's P/E ratio is N/A. In terms of profitability, AFIB's ROE is +1.24%, compared to EYES's ROE of -0.26%. Regarding short-term risk, AFIB is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs INGN Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, INGN has a market cap of 193.5M. Regarding current trading prices, AFIB is priced at $0.00, while INGN trades at $7.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas INGN's P/E ratio is -6.26. In terms of profitability, AFIB's ROE is +1.24%, compared to INGN's ROE of -0.15%. Regarding short-term risk, AFIB is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs TLSI Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, TLSI has a market cap of 192.5M. Regarding current trading prices, AFIB is priced at $0.00, while TLSI trades at $5.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas TLSI's P/E ratio is -4.61. In terms of profitability, AFIB's ROE is +1.24%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, AFIB is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs PROF Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, PROF has a market cap of 184.2M. Regarding current trading prices, AFIB is priced at $0.00, while PROF trades at $6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas PROF's P/E ratio is -5.07. In terms of profitability, AFIB's ROE is +1.24%, compared to PROF's ROE of -0.70%. Regarding short-term risk, AFIB is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs ELMD Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, ELMD has a market cap of 181.8M. Regarding current trading prices, AFIB is priced at $0.00, while ELMD trades at $21.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas ELMD's P/E ratio is 27.44. In terms of profitability, AFIB's ROE is +1.24%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, AFIB is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs BDMD Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, BDMD has a market cap of 162M. Regarding current trading prices, AFIB is priced at $0.00, while BDMD trades at $4.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas BDMD's P/E ratio is 9.25. In terms of profitability, AFIB's ROE is +1.24%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, AFIB is less volatile compared to BDMD. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs ANIK Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, ANIK has a market cap of 155.3M. Regarding current trading prices, AFIB is priced at $0.00, while ANIK trades at $10.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas ANIK's P/E ratio is -14.44. In terms of profitability, AFIB's ROE is +1.24%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, AFIB is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs CVRX Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, CVRX has a market cap of 152.8M. Regarding current trading prices, AFIB is priced at $0.00, while CVRX trades at $5.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas CVRX's P/E ratio is -2.74. In terms of profitability, AFIB's ROE is +1.24%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, AFIB is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs RPID Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, RPID has a market cap of 152.5M. Regarding current trading prices, AFIB is priced at $0.00, while RPID trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas RPID's P/E ratio is -3.38. In terms of profitability, AFIB's ROE is +1.24%, compared to RPID's ROE of -0.56%. Regarding short-term risk, AFIB is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs LNSR Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, LNSR has a market cap of 149.4M. Regarding current trading prices, AFIB is priced at $0.00, while LNSR trades at $12.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas LNSR's P/E ratio is -2.58. In terms of profitability, AFIB's ROE is +1.24%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, AFIB is less volatile compared to LNSR. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs AVR Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, AVR has a market cap of 149.2M. Regarding current trading prices, AFIB is priced at $0.00, while AVR trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas AVR's P/E ratio is -1.15. In terms of profitability, AFIB's ROE is +1.24%, compared to AVR's ROE of -2.92%. Regarding short-term risk, AFIB is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs RCEL Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, RCEL has a market cap of 135.1M. Regarding current trading prices, AFIB is priced at $0.00, while RCEL trades at $5.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas RCEL's P/E ratio is -2.33. In terms of profitability, AFIB's ROE is +1.24%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, AFIB is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs LUCD Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, LUCD has a market cap of 128.8M. Regarding current trading prices, AFIB is priced at $0.00, while LUCD trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas LUCD's P/E ratio is -1.02. In terms of profitability, AFIB's ROE is +1.24%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, AFIB is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs OWLT Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, OWLT has a market cap of 127.1M. Regarding current trading prices, AFIB is priced at $0.00, while OWLT trades at $7.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas OWLT's P/E ratio is -4.78. In terms of profitability, AFIB's ROE is +1.24%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, AFIB is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs ICAD Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, ICAD has a market cap of 105.9M. Regarding current trading prices, AFIB is priced at $0.00, while ICAD trades at $3.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas ICAD's P/E ratio is -20.29. In terms of profitability, AFIB's ROE is +1.24%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, AFIB is less volatile compared to ICAD. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs LUNG Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, LUNG has a market cap of 104.3M. Regarding current trading prices, AFIB is priced at $0.00, while LUNG trades at $2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas LUNG's P/E ratio is -1.80. In terms of profitability, AFIB's ROE is +1.24%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, AFIB is less volatile compared to LUNG. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.
AFIB vs MGRM Comparison
AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFIB stands at 53.8K. In comparison, MGRM has a market cap of 102.4M. Regarding current trading prices, AFIB is priced at $0.00, while MGRM trades at $2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFIB currently has a P/E ratio of -0.01, whereas MGRM's P/E ratio is -5.74. In terms of profitability, AFIB's ROE is +1.24%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, AFIB is less volatile compared to MGRM. This indicates potentially lower risk in terms of short-term price fluctuations for AFIB.